Insulet Corporation (PODD)

Market Cap	22.03B
Revenue (ttm)	2.20B
Net Income (ttm)	402.20M
Shares Out	70.37M
EPS (ttm)	5.55
PE Ratio	56.42
Forward PE	70.28
Dividend	n/a
Ex-Dividend Date	n/a

Volume	713,119
Open	309.40
Previous Close	309.83
Day's Range	305.07 - 313.35
52-Week Range	173.00 - 329.33
Beta	1.38
Analysts	Strong Buy
Price Target	320.11 (+2.27%)
Earnings Date	Aug 7, 2025

About PODD

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; and Omnipod DASH insulin management system that features a Bluetooth enabled pod that is cont...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: May 15, 2007
• Employees: 3,900
• Stock Exchange: NASDAQ
• Ticker Symbol: PODD
• Website: https://www.insulet.com

Financial Performance

In 2024, Insulet's revenue was $2.07 billion, an increase of 22.07% compared to the previous year's $1.70 billion. Earnings were $418.30 million, an increase of 102.76%.

Analyst Forecast

According to 19 analysts, the average rating for PODD stock is "Strong Buy." The 12-month stock price forecast is $320.11, which is an increase of 2.27% from the latest price.

Price Target

$320.11

(2.27% upside)

Analyst Consensus: Strong Buy